Alaunos Therapeutics (NASDAQ:TCRT) Shares Up 13.8%

Shares of Alaunos Therapeutics, Inc. (NASDAQ:TCRT) shot up 13.8% during mid-day trading on Friday . The stock traded as high as $1.34 and last traded at $1.32. 50,846 shares were traded during trading, a decline of 73% from the average session volume of 185,626 shares. The stock had previously closed at $1.16.

Alaunos Therapeutics Trading Up 13.8 %

The company’s fifty day moving average price is $1.71 and its 200-day moving average price is $1.57.

Hedge Funds Weigh In On Alaunos Therapeutics

An institutional investor recently bought a new position in Alaunos Therapeutics stock. Magnolia Capital Advisors LLC acquired a new position in Alaunos Therapeutics, Inc. (NASDAQ:TCRT) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 432,969 shares of the company’s stock, valued at approximately $56,000. Magnolia Capital Advisors LLC owned about 0.18% of Alaunos Therapeutics as of its most recent SEC filing. 27.72% of the stock is owned by institutional investors and hedge funds.

Alaunos Therapeutics Company Profile

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor engine.